Novo Nordisk

Novo Nordisk delivered the second-worst 12-month performance among global pharma mega-caps in 2025: from $146 to currently $47, a drawdown of -68% peak-to-trough. That would be unspectacular for a cyclical industrial — for the GLP-1 queen with 24% revenue growth and 67% EPS growth it is a remarkable valuation reset. What happened?

Three factors together: first, CagriSema (cagrilintide plus semaglutide combination) disappointed in the December 2024 phase-3 readout with only 22% weight loss instead of the hoped-for 25%+ — the market had expected Lilly Tirzepatide-like figures. Second, Eli Lilly established a clear efficacy lead with Zepbound (tirzepatide) and the early retatrutide pipeline. Third, Trump tariff threats on European pharma imports further weighed on the already strained US Wegovy market outlook.

But the 2026 comeback setup is real: Q1 delivered +12% growth at improved margins, the new cardiovascular indication for semaglutide (SELECT trial) lifts Wegovy from pure lifestyle bucket to therapeutic mainstream bucket — with expanded Medicare coverage. At P/E 10.9 and forward P/E 13.8, the stock is extremely undervalued for a 24% growth story — if the thesis holds.

The NVO 13F story in 2025 was a mass exodus. Capital Group reduced by 35% (was 145M ADRs, now 95M). T Rowe Price reduced by 28%. Wellington completely closed its position in Q3/2025. These sales played out primarily after the December 2024 CagriSema readout and accelerated in H2/2025.

But Q1/2026 sentiment is turning: Stanley Druckenmiller built a new NVO position in Q1/2026 — 1.7M ADRs (worth ~$80M), classic contrarian setup after a 60%+ drawdown. Renaissance Technologies also newly opened with 850K ADRs. Baillie Gifford (long-term growth specialist) raised its position by 18%.

Insider activity: CEO Lars Fruergaard Jorgensen did not sell any shares in February 2026 for the first time since 2022 — notable in the historically sale-active Novo Foundation structure. Novo Holdings Foundation (controls 28% of voting rights) executed no sales.

NVO trades at P/E 10.9 (TTM) and forward P/E 13.8 — both unusually low for a growth story. Three valuation scenarios: (1) Bull case: at 22% growth through 2028, 30% net margin and P/E 19 (mean reversion): fair value $85 (+80% upside). (2) Base case: at 16% growth (slowdown due to Lilly competition), 27% margin and P/E 16: fair value $62 (+32% upside). (3) Bear case: at 8% growth (Lilly retatrutide shock), 24% margin and P/E 13: fair value $42 (-11% downside). Asymmetry: clearly positive. The stock is currently pricing a worst-case scenario that is only partially likely. At a 50/30/20 probability weighting of the three scenarios: expected fair value $66 (+40%).

1. Q3 2026: Lilly retatrutide phase-3 data — biggest binary event for Novo; on good retatrutide data -20% NVO, on disappointing +25%
2. May 2026: Novo H1 2026 earnings with manufacturing-capacity update — visible volume lift from Catalent integration expected
3. February 2027: Oral semaglutide phase-3 obesity data — alternative dosage form bringing compliance advantage; success would massively expand addressable population

Novo Nordisk in 2026 is the classic pharma contrarian setup: 68% drawdown from peak, P/E below 11, 24% growth — all valuation anomalies. But the drawdown was not without reason: Lilly structurally has a better drug and a better pipeline. The question is not whether Novo reaches $146 again (unlikely), but whether the current valuation overstates the Lilly risk. My take: yes, it does. At forward P/E 13.8 for 16-22% growth, NVO is a clear long candidate for a 12-24-month setup. Stop-loss: $40 (bear-case fair value). Price target: $65-75 in 18 months. Important for international investors: Novo pays dividends via Danish ADRs — 27% Danish withholding tax, of which 15% is creditable via tax treaty, remaining 12% non-creditable. At 3.8% gross yield, net is ~2.2%. Position in my personal portfolio: 2.5% initial, would add at $42 to 4%. Important: do not buy into CagriSema hype — that was a 2024 anti-trade. Novo wins via broader distribution and manufacturing, not via pipeline miracles.